205 related articles for article (PubMed ID: 36627693)
1. Crosstalk between 5-methylcytosine and N
Tian Y; Xiao H; Yang Y; Zhang P; Yuan J; Zhang W; Chen L; Fan Y; Zhang J; Cheng H; Deng T; Yang L; Wang W; Chen G; Wang P; Gong P; Niu X; Zhang X
Mol Cancer; 2023 Jan; 22(1):5. PubMed ID: 36627693
[TBL] [Abstract][Full Text] [Related]
2. Identification of cross-talk between m
Chen YT; Shen JY; Chen DP; Wu CF; Guo R; Zhang PP; Lv JW; Li WF; Wang ZX; Chen YP
J Hematol Oncol; 2020 Mar; 13(1):22. PubMed ID: 32188475
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
4. Coordinated transcriptional and post-transcriptional epigenetic regulation during skeletal muscle development and growth in pigs.
Zhang D; Wu S; Zhang X; Ren S; Tang Z; Gao F
J Anim Sci Biotechnol; 2022 Dec; 13(1):146. PubMed ID: 36457054
[TBL] [Abstract][Full Text] [Related]
5. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.
Li S; Peng F; Ning Y; Jiang P; Peng J; Ding X; Zhang J; Jiang T; Xiang S
J Cell Biochem; 2020 Mar; 121(3):2543-2558. PubMed ID: 31696971
[TBL] [Abstract][Full Text] [Related]
6. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-301b-3p contributes to tumour growth of human hepatocellular carcinoma by repressing vestigial like family member 4.
Guo Y; Yao B; Zhu Q; Xiao Z; Hu L; Liu X; Li L; Wang J; Xu Q; Yang L; Huang D
J Cell Mol Med; 2019 Aug; 23(8):5037-5047. PubMed ID: 31207037
[TBL] [Abstract][Full Text] [Related]
8. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
9. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo.
Yao S; Ye J; Yin M; Yu R
Cancer Lett; 2020 Jul; 483():87-97. PubMed ID: 32268165
[TBL] [Abstract][Full Text] [Related]
10. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
11. lncRNA HOTAIR overexpression induced downregulation of c-Met signaling promotes hybrid epithelial/mesenchymal phenotype in hepatocellular carcinoma cells.
Topel H; Bagirsakci E; Comez D; Bagci G; Cakan-Akdogan G; Atabey N
Cell Commun Signal; 2020 Jul; 18(1):110. PubMed ID: 32650779
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
Liu J; Liu Y; Meng L; Ji B; Yang D
Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
[No Abstract] [Full Text] [Related]
13. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.
Zhang J; Gao J; Hu M; Xu S; Cheng C; Zheng W; Zhang J
Eur J Med Res; 2023 Jan; 28(1):46. PubMed ID: 36707911
[TBL] [Abstract][Full Text] [Related]
14. Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma.
Wang P; Yan Y; Yu W; Zhang H
Cell Prolif; 2019 Jul; 52(4):e12626. PubMed ID: 31033072
[TBL] [Abstract][Full Text] [Related]
15. Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma.
Hlady RA; Sathyanarayan A; Thompson JJ; Zhou D; Wu Q; Pham K; Lee JH; Liu C; Robertson KD
Hepatology; 2019 Feb; 69(2):639-652. PubMed ID: 30136421
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
17. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
[TBL] [Abstract][Full Text] [Related]
18. RNA methylation regulators contribute to poor prognosis of hepatocellular carcinoma associated with the suppression of bile acid metabolism: a multi-omics analysis.
Zhang T; Gu J; Wang X; Luo J; Yan J; Cai K; Li H; Nie Y; Chen X; Wang J
Am J Cancer Res; 2022; 12(7):2989-3013. PubMed ID: 35968321
[TBL] [Abstract][Full Text] [Related]
19. CtBP1 is involved in epithelial-mesenchymal transition and is a potential therapeutic target for hepatocellular carcinoma.
Zhang XL; Huang CX; Zhang J; Inoue A; Zeng SE; Xiao SJ
Oncol Rep; 2013 Aug; 30(2):809-14. PubMed ID: 23756565
[TBL] [Abstract][Full Text] [Related]
20. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
